LEADER 04000nam  22005535  450 
001 9910298426503321
005 20200630171535.0
010   $a3-662-55880-7
024 7 $a10.1007/978-3-662-55880-5
035   $a(CKB)4100000002892558
035   $a(MiAaPQ)EBC5333097
035   $a(DE-He213)978-3-662-55880-5
035   $a(PPN)225547368
035   $a(EXLCZ)994100000002892558
100   $a20180327d2018      u|         0
101 0 $aeng
135   $aurcnu||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aBehavioral Neurobiology of Psychedelic Drugs /$fedited by Adam L. Halberstadt, Franz X. Vollenweider, David E. Nichols
205   $a1st ed. 2018.
210  1$aBerlin, Heidelberg :$cSpringer Berlin Heidelberg :$cImprint: Springer,$d2018.
215   $a1 online resource (434 pages) $cillustrations
225 1 $aCurrent Topics in Behavioral Neurosciences,$x1866-3370 ;$v36
311   $a3-662-55878-5 
327   $aPreface -- Chemistry and structure-activity relationships of psychedelics -- Hallucinogens and serotonin 5-HT2A receptor-mediated signaling pathways -- Effects of hallucinogens on neuronal activity -- Interactions of Hallucinogens with the Glutamatergic System: Permissive Network Effects Mediated Through Cortical Layer V Pyramidal Neurons -- The effects of hallucinogens on gene expression -- Effect of Hallucinogens on Unconditioned Behavior -- Hallucinogens in Drug Discrimination -- Phenomenology, structure and dynamic of psychedelic states -- Serotonergic hallucinogen-induced visual perceptual alterations -- New world tryptamine hallucinogens and the neuroscience of ayahuasca -- Experimental psychosis research and schizophrenia - similarities and dissimilarities in psychopathology -- A review of Hallucinogen Persisting Perception Disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD -- Therapeutic applications of classic hallucinogens -- Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates.
330   $aThis volume brings together the latest basic and clinical research examining the effects and underlying mechanisms of psychedelic drugs. Examples of drugs within this group include LSD, psilocybin, and mescaline. Despite their structural differences, these compounds produce remarkably similar experiences in humans and share a common mechanism of action. Commonalities among the substances in this family are addressed both at the clinical and phenomenological level and at the basic neurobiological mechanism level. To the extent possible, contributions relate the clinical and preclinical findings to one another across species. The volume addresses both the risks associated with the use of these drugs and the potential medical benefits that might be associated with these and related compounds.
410  0$aCurrent Topics in Behavioral Neurosciences,$x1866-3370 ;$v36
606   $aNeurosciences
606   $aPsychopharmacology
606   $aMedicinal chemistry
606   $aNeurosciences$3https://scigraph.springernature.com/ontologies/product-market-codes/B18006
606   $aPsychopharmacology$3https://scigraph.springernature.com/ontologies/product-market-codes/H53010
606   $aMedicinal Chemistry$3https://scigraph.springernature.com/ontologies/product-market-codes/C28000
615  0$aNeurosciences.
615  0$aPsychopharmacology.
615  0$aMedicinal chemistry.
615 14$aNeurosciences.
615 24$aPsychopharmacology.
615 24$aMedicinal Chemistry.
676   $a615.7883
702   $aHalberstadt$b Adam L$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aVollenweider$b Franz X$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aNichols$b David E$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910298426503321
996   $aBehavioral Neurobiology of Psychedelic Drugs$92505675
997   $aUNINA